Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY

Organon & Co.

2024-Q2 EPS reported $1.53 revenue$3,229,000,000

Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.
Non-GAAP adjusted diluted EPS $1.12 (down 15% YoY); GAAP diluted EPS $0.75 (down 21%).
Women's Health +3%, Biosimilars +22% driven by Hadlima launch; Established Brands -1% ex-FX.
FY2024 revenue guidance narrowed to $6.25-6.45B; Adjusted EBITDA margin reaffirmed 31-33%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.